PLoS ONE (Jan 2015)

Cardiac engraftment of genetically-selected parthenogenetic stem cell-derived cardiomyocytes.

  • Tao Yang,
  • Michael Rubart,
  • Mark H Soonpaa,
  • Michael Didié,
  • Peter Christalla,
  • Wolfram-Hubertus Zimmermann,
  • Loren J Field

DOI
https://doi.org/10.1371/journal.pone.0131511
Journal volume & issue
Vol. 10, no. 6
p. e0131511

Abstract

Read online

Parthenogenetic stem cells (PSCs) are a promising candidate donor for cell therapy applications. Similar to embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), PSCs exhibit self-renewing capacity and clonogenic proliferation in vitro. PSCs exhibit largely haploidentical genotype, and as such may constitute an attractive population for allogenic applications. In this study, PSCs isolated from transgenic mice carrying a cardiomyocyte-restricted reporter transgene to permit tracking of donor cells were genetically modified to carry a cardiomyocyte-restricted aminoglycoside phosphotransferase expression cassette (MHC-neor/pGK-hygror) to permit the generation of highly enriched cardiomyocyte cultures from spontaneously differentiating PSCs by simple selection with the neomycin analogue G148. Following engraftment into isogenic recipient hearts, the selected cardiomyocytes formed a functional syncytium with the host myocardium as evidenced by the presence of entrained intracellular calcium transients. These cells thus constitute a potential source of therapeutic donor cells.